Abstract

The rapid expansion of a supercritical solution (RESS) process was used to produce submicron Paracetamol (=Acetaminophen), Mefenamic acid, Nabumetone and Tolbutamide particles. These model drugs have been chosen since different numbers of polymorphs (I & II, I–III and I–V) have been reported in literature. Thus, the aim of this investigation was twofold: to examine the possibility of using the RESS process to produce submicron drug particles and to control the polymorphic properties of drug micro-particles. The unprocessed and micronized particles are characterized by scanning electron microscopy, X-ray diffraction and differential scanning calorimetry.A significant reduction was observed in the particle size and size distribution of the particles produced by RESS. The mean particle size of the processed particles increased in the following order: Mefenamic acid (0.08μm≤x50≤0.16μm)<Paracetamol (0.16μm≤x50≤0.34μm)<Tolbutamide (0.34μm≤x50≤0.45μm)<Nabumetone (0.75μm≤x50≤0.81μm).Under certain temperature (333 and 353K) and pressure (15, 20, 25 and 30MPa) conditions, it was possible to form the favorable Tolbutamide polymorphic form II. Thus, this study demonstrates that the polymorphic characteristics of submicron Tolbutamide particles produced by RESS can be controlled by varying the pre-expansion conditions while the simple static treatment with supercritical CO2 does not induce polymorphic conversion of the drugs investigated.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.